Company / Interest Expense
Bristol Myers Squibb Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.3B
FY2023
5-year range
$656.0M / $1.4B
FY2019-FY2023
Trend
-6.1%
vs FY2022
Sector context
#5 of 44
Health Care
What the data says
Bristol Myers Squibb's interest expense of $1.3B is higher than 89% of companies in the Health Care sector (FY2023). Interest Expense has fluctuated over the past 8 years, ranging from $167M in FY2018 to $1.4B in FY2022.
Based on SEC 10-K filings.
$1.3B in FY2023 with a 5-year CAGR of +51.5%. Top quartile in the Health Care sector.
Increased from $656M to $1.3B over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -2.1%
- 5-Year CAGR
- +51.5%
- 10-Year CAGR
- -
Sector benchmark
+358.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +51.5%, indicating consistent growth.
- In FY2023, interest expense decreased 6.1% year-over-year.
- Ranks #5 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.3B | -6.1% |
| FY2022 | $1.4B | +116.5% |
| FY2021 | $656.0M | -53.8% |
| FY2020 | $1.4B | +624.5% |
| FY2019 | $196.0M | +17.4% |
| FY2018 | $167.0M | -14.8% |
| FY2017 | $196.0M | -3.4% |
| FY2016 | $203.0M | +2.0% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026